Home›Companies›Biotech & Pharma›Genialis

Genialis, Inc.

Updated Oct 29, 2026·Latest SEC filing Dec 31, 2025·Suggest an edit

About Genialis

Genialis is a private company based in Boston, Massachusetts. It has reported $12,123,253 raised in two offerings on Form D since January 2023. Its chief executive is Rafael Rosengarten.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Dec 17, 2025Dec 31, 2025$700,000of $3.0M target2$350KDebt, OptionsRule 506(b)Form D ↗
Jan 19, 2023Jan 31, 2023$11,423,253of $13.8M target10$1.1MEquityRule 506(b)Form D ↗
Total, two offerings$12,123,253

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Genialis's Form D filed Dec 31, 2025.

IL
Ita Lu
Director
CO
Cedric Odje
Director
ES
Elia Stupka
Director
MS
Miha Stajdohar
Executive officer and director
RR
Rafael Rosengarten
President & Chief Executive Officer, director
LA
Luka Ausec
Executive officer

Earlier filings also listed Tjasa Kutin (executive officer, last listed Jan 2023), Nadine Geiser (director, last listed Jan 2023), Hamzeh Abdul-Hadi (director, last listed Jan 2023) and Drew Volpe (director, last listed Jan 2023).

Sources

  1. SECGenialis, Inc. filing history